<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: We evaluated the renoprotective effects as reflected by short-term changes in <z:mp ids='MP_0002871'>albuminuria</z:mp> of dual blockade of the renin-angiotensin system (<z:mp ids='MP_0011356'>RAS</z:mp>) by adding an <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> receptor blocker (ARB) to treatment with maximal recommended doses of an <z:chebi fb="2" ids="35457">ACE inhibitor</z:chebi> (ACEI) in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: A total of 20 patients (17 men and 3 women) with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> along with <z:hpo ids='HP_0000822'>hypertension</z:hpo> and <z:hpo ids='HP_0000112'>nephropathy</z:hpo> were enrolled in this double-blind, randomized, two-period, crossover trial of 8 weeks of treatment with the ARB <z:chebi fb="0" ids="3347">candesartan</z:chebi> 16 mg daily and placebo added in random order to existing treatment with <z:chebi fb="0" ids="43755">lisinopril</z:chebi>/enalapril 40 mg daily or <z:chebi fb="0" ids="3380">captopril</z:chebi> 150 mg daily </plain></SENT>
<SENT sid="2" pm="."><plain>At the end of each treatment period, we evaluated <z:mp ids='MP_0002871'>albuminuria</z:mp> in three 24-h urinary collections by turbidimetry, 24-h ambulatory blood pressure (ABP) using the Takeda-TM2420, and glomerular filtration rate (GFR) by the (51)Cr-EDTA plasma-clearance technique </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: During monoblockade of the <z:mp ids='MP_0011356'>RAS</z:mp> by ACEI treatment, <z:mp ids='MP_0002871'>albuminuria</z:mp> was 706 (349-1,219) mg/24 h [geometric mean (IQR)]; 24-h ABP was 138 +/- 3/72 +/- 2 mmHg (mean +/- SE); and GFR was 77 +/- 6 ml x min(-1) x 1.73 m(-2) (mean +/- SE) </plain></SENT>
<SENT sid="4" pm="."><plain>During dual blockade of the <z:mp ids='MP_0011356'>RAS</z:mp> by addition of <z:chebi fb="0" ids="3347">candesartan</z:chebi> 16 mg daily, there was a mean (95% CI) reduction in <z:mp ids='MP_0002871'>albuminuria</z:mp> of 28 (17-38) compared with ACEI alone (P &lt; 0.001) </plain></SENT>
<SENT sid="5" pm="."><plain>There was a modest reduction in systolic/diastolic 24-h ABP of 3/2 mmHg (-2 to 8 systolic, -2 to 5 diastolic; NS) </plain></SENT>
<SENT sid="6" pm="."><plain>Changes in <z:mp ids='MP_0002871'>albuminuria</z:mp> did not correlate to changes in ABP </plain></SENT>
<SENT sid="7" pm="."><plain>Addition of <z:chebi fb="0" ids="3347">candesartan</z:chebi> 16 mg daily induced a small, insignificant decrease in GFR of 4 (-1 to 9) ml x min(-1) x 1.73 m(-2) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Dual blockade of the <z:mp ids='MP_0011356'>RAS</z:mp> provides superior short-term renoprotection independent of systemic blood pressure changes in comparison with maximally recommended doses of ACEI in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> as well as <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
</text></document>